Director Bisaro Paul buys 7,500 shares of MYGN at $3.685 on 2026-05-14; stock down 26.3% in 30 days.
Bisaro Paul, a director, purchased 7,500 shares at $3.685, bringing his post-transaction holdings to 97,441 shares. The purchase occurred as the stock traded at $3.62 on the filing date, down 26.3% over the prior 30 days and 19.4% over 90 days from a 52-week high of $8.59. MYRIAD GENETICS remains unprofitable with net income of $-34.1M in the latest quarter despite quarterly revenue of $200.4M, and the company faces headwinds including annual revenue decline of -1.6%. The timing of this insider buy coincides with significant recent price weakness, though the available data does not indicate the director's specific motivations or investment thesis.